Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Monday, November 11, 2024, at 10:00 a.m. ET in Boston, MA.
2024年11月06日，費城（美國東部時間）—生物技術公司cabaletta bio, Inc.（納斯達克股票代碼：CABA）是一家處於臨床階段的生物技術公司，專注於開發和推出首款針對患有自身免疫性疾病的患者設計的首款治癒性靶向細胞療法，今天宣佈公司將參加古根海姆（Guggenheim）首屆醫療創新大會上的爐邊聊天，活動將於2024年11月11日（週一）上午10:00在馬薩諸塞州波士頓舉行。
A live webcast of the presentation will be available on the News and Events section of the Company's website at . Replays will be available on the website for 30 days.
本次演示的現場網絡直播將在公司網站的新聞和活動版塊上提供 演示的重播將在網站上提供30天。
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET (REstoring SElf-Tolerance) clinical trials in myositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis and in the RESET-PV sub-study within the DesCAARTes clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio's headquarters and labs are located in Philadelphia, PA.
關於Cabaletta Bio
生物技術公司cabaletta bio（納斯達克股票代碼：CABA）是一家專注於發現和開發具有潛力爲患有自身免疫性疾病患者提供深層持久甚至治癒性治療的臨床階段生物技術公司。CABA平台包括兩種策略：CARTA（用於自身免疫性的嵌合抗原受體T細胞）策略，主要產品候選藥物CABA-201是一種含有4-1Bb的全人類CD19-CAR T細胞，目前正在肌炎、系統性紅斑狼瘡、系統性硬皮病、全身性重症肌無力以及在pemphigus vulgaris的DesCAARTes臨床試驗中的RESEt-PV子研究中進行評估的RESEt（恢復自身耐受性）臨床試驗。此外，CABA平台還包括CAARt（嵌合自身抗體受體T細胞）策略，包括多種臨床階段候選藥物，如粘膜性pemphigus vulgaris的DSG3-CAARt和MuSk相關性重症肌無力的MuSk-CAARt。不斷擴大的CABA平台旨在開發潛在的治癒療法，爲廣泛範圍的自身免疫性疾病患者提供深層持久的反應。cabaletta bio的總部和實驗室位於賓夕法尼亞州費城。
Contacts:
聯繫人：
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
Anup Marda
首席財務官
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
譯文內容由第三人軟體翻譯。
